Aspire Biopharma Holdings, Inc. (ASBP) - 10-K Summary
Business Context and Reporting Period
Company: Aspire Biopharma Holdings, Inc.
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Aspire is an early-stage biopharmaceutical company developing novel sublingual delivery mechanisms for drugs and nutraceuticals. The company completed a reverse recapitalization with PowerUp Acquisition Corp. on February 17, 2025. Its lead product candidate is a high-dose sublingual aspirin ("Instaprin") intended for the treatment of suspected acute myocardial infarction. The company also markets nutraceuticals, including a caffeine supplement ("Buzz Bomb").
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Net Revenue | $6,202 | $0 |
| Cost of Revenue | $6,318 | $0 |
| Gross Margin | ($116) | $0 |
| Operating Expenses | $19,351,175 | $1,210,871 |
| Net Loss | ($24,480,848) | ($1,309,872) |
| Cash and Cash Equivalents (Dec 31, 2025) | $1,003,904 | $3,633 |
| Working Capital Deficit | ($6,280,667) | N/A |
| Accumulated Deficit | ($27,258,081) | ($2,777,233) |
Note: The filing text does not provide a specific "Profit" figure as the company is in a loss position. Cash flow from operating activities was negative $4,923,488, while financing activities provided $5,923,759.
Material Changes vs. Prior Period
- Revenue Generation: The company commenced revenue generation in Q3 2025 from nutraceutical sales, resulting in $6,202 in revenue compared to zero in 2024.
- Expense Surge: General and Administrative (G&A) expenses increased by $16.7 million (1,775%) to $17.6 million, driven by professional services, stock-based compensation ($14.1 million), and public company costs. R&D and Sales/Marketing expenses also increased significantly.
- Reverse Recapitalization: The company completed a reverse merger in February 2025, changing its name and legal structure, which triggered significant non-cash stock-based compensation and transaction costs.
- Debt Activity: The company issued and subsequently converted or repaid multiple rounds of convertible notes and debentures totaling over $13 million in principal during the year, resulting in substantial interest expense ($8.5 million) and losses on extinguishment of debt.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance:
- Product Pipeline: The company plans to submit a 505(b)(2) New Drug Application (NDA) to the FDA for its high-dose sublingual aspirin in late 2026, following a planned clinical trial in mid-2026.
- Commercialization: No sales infrastructure exists for pharmaceutical products yet. The company plans to build a sales force or license the technology upon approval.
- Capital Needs: Management explicitly states that the company requires substantial additional financing to achieve its goals. Failure to obtain capital could force delays or termination of operations.
Risks and Contingencies:
- Going Concern: The auditor has issued a "Substantial Doubt" opinion regarding the company's ability to continue as a going concern due to the accumulated deficit and working capital deficit.
- Regulatory Risk: The sublingual delivery mechanism is unproven; FDA approval is not guaranteed. The company previously faced Nasdaq delisting notices for bid price and market value deficiencies but regained compliance in February 2026.
- Intellectual Property: Some previously acquired patents expired, though the company has filed new applications covering its current formulations.
- Management Turnover: The company experienced changes in CEO and Board composition during the reporting period.
Unusual Items:
- Stock-Based Compensation: A one-time charge of $14.1 million was recorded for advisory shares issued upon the consummation of the reverse recapitalization.
- Debt Extinguishment: A loss of $364,109 was recorded due to the amendment of the Blackstone Note.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $1.0 million cash balance against the $6.3 million working capital deficit and the timeline for the next financing round.
- Going Concern Status: Review the specific plans management has outlined to raise capital and mitigate the "substantial doubt" raised by the auditor.
- Regulatory Milestones: Confirm the status of the FDA Pre-IND meeting response and the timeline for the next clinical trial (planned for summer 2026).
- Dilution Risk: Assess the potential dilution from the $100 million Equity Line of Credit (ELOC) and the recent Series A Preferred Stock offering ($11 million gross proceeds).
- Revenue Sustainability: Evaluate the scalability of the $6,202 nutraceutical revenue stream versus the high burn rate of the pharmaceutical development.